Cardiology

The FDA has approved Verily’s Study Watch, a wearable medical device that conducts electrocardiograms (ECGs).

The hypertension medication is again being recalled due to carcinogenic impurities.

Coronary artery disease remains the top killer of Americans—these tools may help identify people who are still at risk.

The FDA has responded to the Janssen Pharmaceutical company's sNDA with a request for more data.

Improvements in muscle and cardiac function were observed for 18 months in tested mice.

The Amplatzer Piccolo Occluder is implanted via catheter to repair patent ductus arteriosus in newborns weighing as little as 2 pounds.

The FDA has approved RFPi Inc’s blood flow and perfusion imaging medical device, iCertainty.

How well do you know your CV outcomes trial data for novel type 2 diabetes drugs? Your answers to these 8 questions will tell. 

The WEB Aneurysm Embolization System is designed to treat intracranial wide neck bifurcation aneurysms.

Higher incidences of epilepsy in children with congenital heart disease prompted a neurocardiology team to call for increased perioperative EEG monitoring.

Once one of the country healthcare system's greatest successes, CVD and related mortality is rising again. What's its true cause?

The community-based program intent on improving black men's blood pressure care will revamp its practice headed into 2019.

This past year came with a multitude of new FDA approvals for antiretroviral therapies as well as research highlighting HIV and various comorbidities.

African-American patients with moderate or severe sleep apnea have twice, or 3.5 times, the risk of resistant hypertension, respectively.

Providers should be aware that periodontal disease may hinder the efficacy of blood pressure medication.

The seemingly complicated maneuvers of getting patient’s cholesterol better can be resolved with common sense. What’s best for the patient?

Since the PCSK9 inhibitors were approved for cholesterol management by the FDA in 2015, they have been frequently compared.

Wiviott, senior investigator of the DECLARE-TIMI 58 trial, says that SGLT2 inhibitors and GLP-1 receptor agonists are changing the paradigm of how clinicians manage diabetes and cardiovascular risk.

A new study found the annual top-50 ranking is a reliable indicator of cardiovascular disease mortality and patient satisfaction.

Topline data shows that the diabetes medication is non-inferior to placebo with regard to a composite outcome of major adverse cardiovascular events.

Prevalence of hypertension in HIV-positive persons is not attributed to antiretroviral drug treatment in largest adverse event surveillance study.

The septic shock therapy was approved by the FDA last December. How has it fared in its first year of real-world clinical use?

How fatty liver disease and NASH—as well as the comorbidities associated with them—highlighted this year's discussions.

Jay Edelberg, MD, PhD, of Sanofi and Robert Sanchez, PhD, of Regeneron shared about the recent ODYSSEY OUTCOMES trial of alirocumab (Praluent) and accompanying cost-effectiveness study.

“Reassuring” results from a study of 11,692 individuals show that statin use does not affect the effectiveness of the influenza vaccine.